Why the study?
Aspirin has anti-inflammatory, antiplatelet, and direct antibacterial effects that may improve survival in sepsis, but the relationship between prehospital aspirin use and sepsis outcomes required evaluation.
Does prehospital aspirin use reduce 90-day mortality in patients with sepsis?
Does prehospital aspirin use reduce 90-day mortality in patients with sepsis?
Prehospital aspirin use is associated with a modest but statistically significant reduction in 90-day mortality among patients presenting with sepsis.
Answers are grounded in this paper and cite their sources.
Prehospital aspirin was associated with lower 90-day sepsis mortality; leaves open whether RCTs should test causality.
BACKGROUND: Aspirin has anti-inflammatory and antiplatelet activities and directly inhibits bacterial growth. These effects of aspirin may improve survival in patients with sepsis. We retrospectively reviewed a large national health database to test the relationship between prehospital aspirin use and sepsis outcomes. METHODS: We conducted a retrospective population-based cohort study using the National Health Insurance Research Database of Taiwan from 2001 to 2011 to examine the relationship between aspirin use before hospital admission and sepsis outcomes. The association between aspirin use and 90-day mortality in sepsis patients was determined using logistic regression models and weighting patients by the inverse probability of treatment weighting (IPTW) with the propensity score. Kaplan-Meier survival curves for each IPTW cohort were plotted for 90-day mortality. For sensitivity analyses, restricted mean survival times (RMSTs) were calculated based on Kaplan-Meier curves with 3-way IPTW analysis comparing current use, past use, and nonuse. RESULTS: Of 52,982 patients with sepsis, 12,776 took aspirin before hospital admission (users), while 39,081 did not take any antiplatelet agents including aspirin before hospital admission (nonusers). After IPTW analysis, we found that when compared to nonusers, patients who were taking aspirin within 90 days before sepsis onset had a lower 90-day mortality rate (IPTW odds ratio [OR], 0.90; 95% confidence interval [CI], 0.88-0.93; P < .0001). Based on IPTW RMST analysis, nonusers had an average survival of 71.75 days, while current aspirin users had an average survival of 73.12 days. The difference in mean survival time was 1.37 days (95% CI, 0.50-2.24; P = .002). CONCLUSIONS: Aspirin therapy before hospital admission is associated with a reduced 90-day mortality in sepsis patients.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: